Hi Marjolijn,
Joseena referenced the 2021-Geanon et al COVID paper, which is probably this one:
https://doi.org/10.1002/cyto.a.24317In this case, the workflow was that the collection site would draw blood, do the MDIPA staining, then fix and freeze the MDIPA-stained WB for eventual shipping to a central facility. That central facility would then perform barcoding, intracellular staining, Ir staining, and then run the sample.
This was also the basic protocol for the large NIH COVID19 IMPACC study: 12-14 collection sites around the US would draw the blood, stain with MDIPA, then fix with PROT1 and freeze at -80C. Then, periodically, they would make a large shipment of samples to Stanford or Mt Sinai (6-7 collection sites to Stanford, 6-7 different collection sites to Mt Sinai) who would then do the rest of the experiment.
As such, the protocol was designed to allow MDIPA staining of fresh WB (which allows the chemokine receptors to stain properly), but then allow a stopping point in the protocol after surface stain so that samples could be banked.
I don't know if Joseena's study is doing any intracellular staining or not (or if there's even more than one blood collection site), but banking would still allow them to bank samples until they have a full 20plex amount of samples, to run the samples more efficiently.
So, the application note method of carrying the staining all the way through to Ir before freezing may not be the optimal workflow for them.
One other question: looking at the application note, it states:
"2. Aspirate supernatant leaving ~100 μL residual volume of iridium fix/perm solution.
3. Resuspend the cell pellet in residual volume and transfer into a labeled 1.5 mL microcentrifuge tube.
4. Place 1.5 mL tubes in a plastic container for storage at –80 ºC"
In contrast to Riley's comment about "cryopreservation media" (presumably FBS/DMSO), this application note seems to imply that the sample is frozen at -80C in Ir-Fix-Perm.
Is that correct? If so, I'm surprised, we have not had great success in freezing fully-stained samples in anything other than FBS/DMSO. In particular, we start to see small but noticeable and reproducible losses in Monocytes and B cells in particular.
Mike